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Adjuvant formulated virus-like particles expressing native-like
forms of the Lassa virus envelope surface glycoprotein are
immunogenic and induce antibodies with broadly neutralizing
activity
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Andreas Kaufmann2, Stefan Bauer2, Stephan Becker1,6, Veronika von Messling 6,7,9 and Thomas Strecker 1✉
Lassa mammarenavirus (LASV) is a rodent-borne arenavirus endemic to several West African countries. It is the causative agent of
human Lassa fever, an acute viral hemorrhagic fever disease. To date, no therapeutics or vaccines against LASV have obtained
regulatory approval. Polyclonal neutralizing antibodies derived from hyperimmunized animals may offer a useful strategy for
prophylactic and therapeutic intervention to combat human LASV infections. The LASV envelope surface glycoprotein complex (GP)
is the major target for neutralizing antibodies, and it is the main viral antigen used for the design of an LASV vaccine. Here, we
assessed the immunogenic potential of mammalian cell-derived virus-like particles (VLPs) expressing GP from the prototypic LASV
strain Josiah in a native-like conformation as the sole viral antigen. We demonstrate that an adjuvanted prime-boost immunization
regimen with GP-derived VLPs elicited neutralizing antibody responses in rabbits, suggesting that effective antigenic epitopes of GP
were displayed. Notably, these antibodies exhibited broad reactivity across five genetic lineages of LASV. VLP-based immunization
strategies may represent a powerful approach for generating polyclonal sera containing cross-reactive neutralizing antibodies
against LASV.
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INTRODUCTION
Lassa mammarenavirus (LASV), an Old World member of the family
Arenaviridae, is the zoonotic agent of human Lassa fever (LF),
which is endemic to several West African countries and affects an
estimated 100,000–300,000 people annually1,2. While most cases
of LF are asymptomatic or have mild symptoms, 20% of infections
result in clinical manifestations varying from flu-like syndromes to
fatal hemorrhagic fevers. The only drug with proven efficacy is the
nucleoside analog ribavirin; however, treatment is only effective at
an early stage of infection and is associated with adverse drug
reactions3. Since no licensed therapeutic approaches or protective
vaccines are yet available, LASV represents a severe public health
problem in the affected regions. LF has been listed in the WHO
R&D Blueprint of priority diseases requiring urgent research and
development attention4. Ongoing large LF outbreaks associated
with high case fatality rates in Nigeria underscore the critical need
for accelerated research activities toward approved therapeutics
and vaccines5. Furthermore, LASV is one of the most common viral
hemorrhagic fever agents in risk group 4 exported to countries
outside the endemic areas.
LASV is a lipid-enveloped virus that contains a single-stranded,
bi-segmented RNA genome with an ambisense coding strategy.
The envelope glycoprotein complex (GP) is exposed on the
surface of the virus as trimeric spikes and is the main target for
antibody-based therapeutics and vaccine design. Initially, the
glycoprotein open reading frame (ORF) codes for an immature
precursor polyprotein (referred to as GPC)6. A sequence of co- and
posttranslational cleavage events by signal peptidase and the host
cell convertase SKI-1/S1P generates the glycoprotein subunits
stable signal peptide (SSP), GP1 and GP2, which remain associated
through non-covalent interactions7,8. Proteolytic maturation is
essential for GP function and virus infectivity7.
Fully assembled GP on the viral surface is displayed as a trimer
of heterodimers composed of GP1 and GP2, which mediate
binding to host cell receptors and virus–host membrane fusion,
respectively9–12. A unique structural feature of GP from LASV and
other arenaviruses is that SSP remains associated with the
glycoprotein spike complex through interaction with GP2. SSP
plays important roles in the maturation and assembly of GP as well
as in the membrane fusion process required for virus entry
(reviewed in ref. 13). In addition to SSP, the cytoplasmic domain of
GP2 is a critical component for the stability and conformation of
the external immunogenic GP domains14. Furthermore, the GP
spike is extensively glycosylated, with ~30% of its mass consisting
of host-derived N-linked glycans15. These N-linked glycans are
essential for correct folding, cleavage, and transport of GP and
also for efficient viral entry and infectivity15–17. The high density of
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glycans on the GP surface is thought to shield the underlying
protein from efficient immune surveillance18,19. Despite this
immunological escape mechanism, neutralizing antibodies (nAbs)
can emerge in individuals who recovered from LF. However, it is
widely accepted that T-cell responses play the central role in
controlling acute LASV infection and are the driving force of
clinical improvement since nAbs do not appear until the late stage
of convalescence and are detected only in low-to-moderate
titers20,21.
Several GP-based vaccine candidates against LASV have shown
to be effective in preventing the fatal outcome of LF disease in
preclinical animal testing. These include various approaches, such
as live attenuated arenavirus vaccines (e.g., the natural reassortant
ML29 or recombinant Mopeia virus)22,23, viral vector-based
vaccines (e.g., modified Vaccinia virus, vesicular stomatitis virus
(VSV), measles virus, rabies virus, and yellow fever virus)24–29, and
DNA-based vaccines30,31. Both humoral and cell-mediated
immune responses are assumed to contribute to vaccine-
mediated protection; however, immune markers that correlate
with protective immunity differ between vaccine platforms32.
Notably, repeated immunization of nonhuman primates with
purified LASV particles that have been inactivated by gamma
irradiation failed to protect animals33. While the antibody
response had the same magnitude as that found in humans
who had recovered from LF, vaccine-induced antibodies exhibited
no neutralizing activity. The lack of protection was also assumed
to be associated with a limited ability of the inactivated LASV
vaccine to elicit a robust cell-mediated immune response.
In addition to prophylactic vaccination, passive antibody-
mediated immunotherapy has gained renewed interest for the
treatment of LF. Convalescent plasma (CP) therapy has shown
controversial results in clinical and preclinical settings. Early
studies in humans and animal models demonstrated enhanced
survival or even complete protection against LF following the
administration of CP. Several factors were identified for effective
LF therapy and treatment success, such as the time of CP
administration post infection, the nAb concentration, and the
antigenic matching of the CP preparation20,21,34–36. In contrast to
these studies, a controlled clinical CP trial indicated that passive
antibody transfer did not protect recipients from fatal LF3.
Recently, monoclonal antibodies with high neutralizing capacity
against GP derived from memory B cells of LF survivors have been
shown to provide protection against LF in a nonhuman primate
model, supporting the concept of passive antibody therapy.
Moreover, treatment with these monoclonal antibodies resulted in
complete survival even when administered at advanced stages of
the disease, underscoring the beneficial effect of nAbs in the
treatment of severe LF37.
Although protective monoclonal antibodies represent powerful
therapeutic tools, the logistical and experimental procedures
required for the generation of human B-cell-derived nAbs from
convalescent donors are time and cost intensive. In addition, slight
changes in the epitope structure may render a monoclonal
antibody unable to recognize the target antigen. In light of the
high genetic diversity of LASV, the possible emergence of
antigenically distinct LASV strains with epidemic potential
suggests a need for alternative strategies for the generation of
rapidly available therapeutic antibodies with neutralizing capacity,
particularly in the early phase of an outbreak when convalescent
donor material is not yet available. Polyclonal antibodies that have
high neutralizing activity against LASV and are derived from
hyperimmunized animals could represent an alternative means of
rapidly producing therapeutic antibodies for the treatment of LF,
as has been described for Ebola virus38–40.
Efficient neutralization of LASV correlates with antibody binding
to the functional forms of trimeric GP41,42. As discontinuous
epitopes presented on structurally mature and properly
assembled GP are the relevant targets for nAbs, the most
desirable GP-based immunogen should closely mimic the native
trimeric spike structure as it is displayed on the viral surface. Virus-
like particles (VLPs) have been explored for a variety of viruses as a
means of preserving the functional and structural native
glycoprotein form and thus the antigenic conformation in their
natural lipid membrane environment. Due to their ordered
repetitive surface structures as well as their morphological
similarity to authentic viruses, VLPs have been shown to stimulate
host immune cells efficiently, eliciting both humoral and cellular
immune responses. For example, vaccination with VLPs derived
from the highly pathogenic filoviruses, Ebola and Marburg virus,
has shown protection from lethal virus infection in various animal
models43–45. In addition to their suitability as vaccine platforms,
VLPs have been used to generate pathogen-specific neutralizing
antisera with therapeutic potential for the treatment of viral
infections46. We previously described that the sole expression of
LASV GP in mammalian cells is sufficient to produce VLPs
displaying GP in its trimeric form on the envelope surface that
closely mimic the structure of the virion-associated spike47–49. In
this proof-of-concept study, we assessed the immunogenicity of
adjuvanted GP-derived VLPs in rabbits. We show that the GP VLPs
elicited a nAb response against LASV, suggesting that critical
epitopes of GP were displayed. Our data suggest that the use of
GP-derived VLPs is a safe and practical strategy for the generation
of neutralizing polyclonal antibodies against LASV.
RESULTS
Production of LASV GP VLPs for use as an antigen
The GP of LASV mediates virus attachment and virus entry into
human cells and is the sole target for the induction of nAbs. Due
to their ability to display viral envelope glycoproteins in their
native form, VLPs are suitable candidates for the induction of
robust immune responses. Here, we aimed to assess the
immunogenic potential of mammalian cell-derived VLPs that
display LASV GP from the prototypic strain Josiah in its mature,
fully glycosylated form (Fig. 1a). To facilitate large-scale production
of the GP VLPs, we used our previously established Madin–Darby
canine kidney strain II (MDCK II) cell line that stably expresses LASV
GP and constitutively produces GP VLPs47. As shown in Fig. 1b,
western blot analysis using an LASV GP1-specific monoclonal
antibody and LASV GP2-specific polyclonal antibodies confirmed
the presence of the GP1 and GP2 subunits in the VLPs purified
from the cell culture supernatant by ultracentrifugation through a
20% sucrose cushion. Electron microscopic analysis of negative-
stained VLPs revealed pleomorphic particles of different sizes that
displayed GP spikes on their surfaces (Fig. 1c). As canine-derived
MDCK II cells do not represent a natural host cell type for LASV,
and recombinantly generated GP may not resemble native-like
glycosylation of infectious LASV particles, we analyzed the
glycosylation status of GP expressed on the surface of VLPs in
comparison with GP present on authentic LASV virions purified
from infected MDCK II cells. In addition, we assessed the
glycosylation profile of GP from purified LASV virions released
from infected human-derived HuH7 cells as well as Baby hamster
kidney (BHK) cells that mimic virus shedding from rodents.
Enzymatic deglycosylation assays using endo-β-N-acetylglucosa-
minidase H (EndoH) and PNGaseF digestion showed that the
glycosylation profile of GP from both VLPs and authentic LASV
secreted from MDCK II cells closely resembles that of naturally
occurring LASV particles released from human and rodent cells.
Recombinantly expressed GP on the surface of VLPs and GP on the
surface of infectious LASV particles released from all mammalian
cell lines tested were equally sensitive to endoglycosidase
treatments and exhibited similar migration patterns in SDS-PAGE
gels (Fig. 1d). The purified GP VLPs were subsequently used to
determine their suitability as immunogens. Therefore, two New
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Zealand White rabbits were immunized intramuscularly with
300 μg VLPs mixed in a 1:1 ratio with squalene-containing
water-in-oil Sigma Adjuvant, which was recently demonstrated
to enhance the induction of functional antibody titers against
Ebola virus and Nipah virus46. Both rabbits received three booster
injections with the adjuvanted GP VLP preparation at day 28, day
49, and day 70, as depicted in the schematic representation of the
immunization scheme (Fig. 1e). Blood samples were taken at day 0
and immediately before each boost. Final blood samples were
collected on day 77. IgG antibody responses against LASV GP were
assessed by immunofluorescence and immunoelectron micro-
scopy analysis, immunoperoxidase monolayer assay (IPMA), and
enzyme-linked immunosorbent assay (ELISA). Functional activity
of antibodies was determined by antibody neutralization assays
Fig. 1 Production of LASV GP VLPs for use as immunogens. a Schematic representation of LASV GPC. The glycoprotein precursor GPC
consists of the stable signal peptide (SSP) (amino acids 1–58), the receptor-binding subunit GP1 (amino acids 59–259), and the fusion-
mediating subunit GP2 (amino acids 260–491) containing a transmembrane domain (TM) and a cytoplasmic domain (CD). The signal
peptidase (SPase) cleavage site (after amino acid 58), the SKI-1/S1P cleavage site (after amino acid 259), and potential glycosylation sites (Y)
are indicated. b Western blot analysis of LASV GP VLPs purified from the cell culture supernatant of MDCK II cells stably expressing LASV GP
using primary antibodies against GP1 (mouse AC1) and GP2 (rabbit α4). c Electron micrograph of negatively stained, purified GP VLPs. Scale
bar, 100 nm. d Western blot analysis of LASV GP after treatment with endoglycosidases. LASV GP VLPs released from MDCK II LASV GP cells
and authentic LASV purified from infected MDCK II cells, HuH7 cells, or BHK cells were treated with either endo-β-N-acetylglucosaminidase H
(EndoH) or N-glycosidase F (PNGaseF). GP subunits were detected with primary antibodies against GP1 (mouse AC1) and GP2 (rabbit α4),
respectively. e Schematic diagram of the immunization protocol. New Zealand White rabbits were immunized intramuscularly with 300 μg
VLPs mixed with Sigma Adjuvant and boosted 28, 49, and 70 days after the first immunization. Serum samples were taken at day 0 and
immediately before each boost. Final blood collection was performed on day 77.
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using authentic LASV and two surrogate systems for the study of
neutralization under BSL2 containment conditions.
Induction of LASV GP-specific antibodies in rabbits immunized
with adjuvanted GP VLPs
First, we evaluated the immune sera of both rabbits taken at
exsanguination on day 77 for their ability to recognize LASV GP by
immunofluorescence microscopy. To this end, we used either
MDCK II cells stably expressing GP or Vero E6 cells transiently
expressing GP. The D0 pre-immune sera of both rabbits were used
as controls to exclude nonspecific binding of the polyclonal sera.
Figure 2a, b shows that both immune sera (Rb#347_D77 and
Rb#350_D77) recognize GP in its native conformation in live MDCK
II and Vero E6 cells. In contrast, cells stained with the pre-immune
sera did not show evidence of nonspecific antibody binding. As
some of the below-mentioned serological techniques for measur-
ing LASV-specific binding antibodies require chemical fixation, we
wanted to assess whether paraformaldehyde (PFA) fixation of cells
expressing GP interferes with antibody binding and antigen
recognition by the rabbit immune sera due to potential PFA-
Fig. 2 Reactivity of GP VLP-immunized rabbit sera against full-length LASV GP. Immunofluorescence microscopy of a MDCK II cells stably
expressing LASV GP or b Vero E6 cells transiently transfected with plasmids encoding LASV GP. For the staining of native antigens, the cells
were incubated with either the pre-immune rabbit sera (D0 samples) or rabbit immune sera after final bleed (D77 samples) before fixation
with 4% PFA. For the staining of fixed antigens, the cells were treated with 4% PFA and permeabilized and then incubated with indicated
rabbit sera. Anti-rabbit Alexa Fluor 488 was used as a secondary antibody, and nuclei were visualized by DAPI staining. Merged images of
LASV GP and nuclear staining are shown. Scale bars, 20 μm. c Immuno-EM of stable transfected (MDCK II LASV GPC cells) and nontransfected
MDCK II cells. For immunogold labeling of GP, the cells were aldehyde fixed, pelleted, and embedded in LR White, and ultrathin sections were
incubated with rabbit serum (Rb#347_D77 or Rb#350_D77) diluted 1:20, followed by protein A conjugated to 6 nm colloidal gold. Scale bars,
250 μm.
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induced structural changes and/or cross-linking of the GP antigen.
However, staining of PFA-treated GP-expressing MDCK II and GP-
transfected Vero E6 cells with both immune sera showed a similar
staining pattern when compared with the staining of GP under
native conditions, suggesting the preservation of antibody
recognition sites within GP after chemical fixation. In addition,
we performed immunoelectron microscopic analysis on ultrathin
sections using the sera samples Rb#347_D77 and Rb#350_D77.
Both rabbit sera recognize GP at the plasma membrane of the
MDCK II LASV GP cells, while only a few gold particles were
detected in untransfected MDCK II control cells (Fig. 2c).
Collectively, our findings indicate that the expression of fully
assembled GP antigen by recombinant VLPs induced LASV GP-
specific binding antibodies.
Quantification and characterization of LASV GP-specific antibodies
We then used IPMA to assess the level of the total IgG response of
the rabbit immune sera against LASV GP. Polyclonal antibody α4
was used as a positive control. As shown in Fig. 3a, serum
Rb#347_D77 exhibited a GP-specific antibody titer of 1:1707, while
serum Rb#350_D77 had an eightfold higher final titer of 1:13,653.
These results show that the LASV GP VLP immunization approach
is immunogenic. It was then of interest to measure the specific
antibody binding responses of the immune sera to either of the
GP1 or GP2 subunits. Therefore, we developed an ELISA using
recombinant LASV GP1 comprising amino acids 59–259 and
recombinant LASV GP2 comprising amino acids 260–426
expressed in HEK293 cells. The purity of the recombinant GP1
and GP2 protein samples was confirmed by SYPRO Ruby protein
gel staining (Fig. 3b). Of note, the presence of a human IgG Fc-tag
Fig. 3 Quantification of LASV GP-specific antibodies. a IPMAs for total IgG against LASV GP of rabbit immune sera after final bleed
(D77 samples) and control antibody (α4) are shown. The initial dilution was 1:16, and the total α-LASV GP titer was calculated as the reciprocal
value of the last serum dilution at which positive staining was detected. Error bars are representative of the standard deviation (SD) and are
calculated from three independent experiments. b SDS-PAGE and SYPRO Ruby protein gel staining analyses of recombinant LASV GP1 and
GP2 domains that were used for ELISA plate coating. Estimated molecular masses are indicated. c Western blot analysis to confirm the
specificity of rabbit control sera (α231 and α3) used for ELISA. Purified GP VLPs and control cell culture supernatant were separated by SDS-
PAGE and blotted to nitrocellulose membranes. The upper blot was stained with mouse AC1 (against GP1) and rabbit α3 (against GP2), while
the lower blot was stained with mouse AC1 and rabbit α231 (against GP1). d ELISA of total IgG against LASV GP1 or GP2 using rabbit control
sera α231 and α3 diluted 1:200 as well as unrelated negative control sera. e ELISA using 1:200 dilution of sera from vaccinated animals (D0 and
D77 samples). Error bars are representative of the SD of OD 450 nm values (duplicate measurement of three independent experiments). The
dashed line depicts the cut-off for a positive antibody response, calculated as the median of the negative control+ 10%. Statistical
significance was calculated using an unpaired t-test (*p value < 0.05).
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and a glycine–serine linker in the recombinant proteins accounts
for the higher molecular weight of GP1 and GP2 in the SDS-PAGE
analysis. As controls for the GP1 and GP2-specific IgG ELISA, we
used our in-house developed LASV GP-specific polyclonal rabbit
sera designated α231 (recognizing LASV GP1) and α3 (recognizing
LASV GP2). The specificity of both sera was confirmed by western
blot analysis using purified LASV GP VLP preparations (Fig. 3c).
ELISA results demonstrate the specific detection of recombinant
GP1 and GP2 by the control sera α231 and α3, respectively, as
indicated by the enhanced optical density (OD) 450 nm value for
the corresponding GP subunit (Fig. 3d). Unrelated rabbit control
serum was used as a negative control for the assay. When we
assessed the serum reactivity from immunized animals toward
either GP1 or GP2, we found that rabbit Rb#347 produced
significantly more binding antibodies against the GP2 subunit in
comparison with the level of binding antibodies against GP1,
77 days after the initial immunization. Conversely, animal Rb#350
generated significantly higher levels of binding antibodies
directed to GP1 compared with the levels of binding antibodies
specific to GP2 (Fig. 3e). No unspecific binding of both pre-
immune sera (D0 samples) from the vaccinated animals was
observed. These data demonstrate that VLP-based immunization
co-formulated with a squalene-based adjuvant elicited antibodies
targeting both GP subunits.
Cross-reaction of polyclonal antibodies to GP of other LASV
lineages and related Old World mammarenaviruses
We then determined if the polyclonal antibodies induced by
immunization of VLPs expressing GP of the lineage IV Josiah strain
have the potential to cross-react with GP from other LASV lineages
and the related Old World mammarenavirus lymphocytic chor-
iomeningitis virus (LCMV). Cross-reactivity was assessed by
immunofluorescence microscopy using Vero E6 cells transiently
expressing GP of the LASV lineages I, II, IV, V, and VII, or LCMV
(Fig. 4). The broadly reactive human monoclonal antibody 37.7H
served as a control41. Besides GP of LASV lineage IV, both rabbit
immune sera effectively recognized the GP of all other LASV
lineages tested. Both sera were also capable of binding to the GP
of LCMV. The high degree of cross-reactive binding properties of
the rabbit immune sera across multiple lineages of LASV and
related Old World arenaviruses is in agreement with previous
observations, demonstrating broad cross-reactivity of monoclonal
anti-GP antibodies isolated from LF survivors41.
nAb responses elicited by LASV GP VLP immunization
The sera from VLP-immunized rabbits were then tested for their
capacity to neutralize the infection of authentic LASV by
immunofocus reduction neutralization assay. As shown in Fig. 5a,
the Rb#347_D77 and Rb#350_D77 sera showed potent neutralizing
activities against their homologous LASV strain Josiah (with IC50
values of 1:354 and 1:449, respectively). Furthermore, both rabbit
immune sera cross-neutralized the infection by a clinical LASV
isolate from lineage II50, although with slightly weaker activity (with
IC50 values of 1:210 and 1:350, respectively). A rabbit- or human-
derived negative control serum exhibited no neutralization activity
against both tested viruses even at the lowest serum dilution. The
monoclonal antibody 37.7H served as a positive control. Our results
indicate that the VLP immunization elicited cross-nAb response in
rabbits.
Broadly neutralizing activity of hyperimmune sera
As we have shown that the VLP-immunized animals have a strong
nAb response to LASV representatives of lineages II and IV, we
decided to investigate if the nAbs elicited were capable of
neutralizing additional LASV lineages. Using a retroviral pseudo-
type system as a BSL2 surrogate model of neutralization, we
produced LASV pseudoviruses (LASVpv) expressing different LASV
GPs representing five different lineages. Glycoprotein G from VSV
was used as a negative control. As shown in Fig. 5b, D77 sera from
both animals were capable of neutralizing all five LASV lineages,
but neither serum was able to neutralize VSV G expressing
pseudoviruses at the highest concentration of sera (1:100),
showing that the neutralization measured was GP specific.
Interestingly, lineage I was the most easily neutralized by sera
from both animals (Rb#347, ID50 value of 1:130; Rb#350, ID50 value
of 1:1507) rather than the homologous Josiah strain. Lineage V
was the most refractive to neutralization, but was still susceptible
(Rb#347, ID50 value of 1:25; Rb#350, ID50 value of 1:373). The
serum from Rb#350 was more potent than that of Rb#347, with
ID50 values ranging from 1:373 to 1:1507, which is reflective of
what was seen in the other assays. Rb#350 was also able to
neutralize lineage I (ID50 value of 1:1507) and lineage II (ID50 value
of 1:1028) better than lineage IV (ID50 value of 1:781). Consistent
with previous results, the monoclonal antibody 37.7H used as a
positive control effectively neutralized the GPs from LASV lineage
II and IV, but exhibited a reduced neutralizing activity toward GP
from LASV lineage I. However, 37.7H failed to neutralize GP from
lineage III, which contrasts previous observations41. The different
neutralizing responses measured in the different assays may stem
Fig. 4 Antibody cross‐reactivity among LASV lineages and related Old World mammarenaviruses. GP of the LASV lineages I, II, IV, V, and VII
or LCMV were vectorially expressed in Vero E6 cells. After fixation, cell monolayers were incubated with the rabbit immune sera Rb#347_D77
and Rb#350_D77, or, as a control, the human monoclonal antibody 37.7H, and analyzed by indirect immunofluorescence microscopy. Cell
nuclei were visualized with DAPI, and merged images are shown. Scale bars, 20 µm.
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from different type of assay formats, which require further
investigations. Altogether, these data show that the nAbs elicited
in VLP-immunized animals are broadly neutralizing, as they inhibit
entry of five different LASV lineages.
Comparison of neutralizing activities
We then measured the level of nAb activity using replication-
competent VSVΔG/LASVGP in which the original VSV glycoprotein
G was replaced by LASV GP as another BSL2 surrogate system51.
As shown in Fig. 5c, D77 sera from the VLP-immunized animals
showed potent neutralizing activities against VSVΔG/LASVGP, with
mean titers of 1:768 for Rb#347 and 1:2048 for Rb#350. In contrast,
the pre-immune control sera (D0 samples) did not exhibit any
neutralization activity at the lowest dilution tested (1:16) and were
therefore denoted as a titer of eight for mean titer calculation.
Monoclonal antibody 37.7H was used as a positive control (mean
titer of 1:117). Both immune sera showed no neutralizing activity
toward wild-type VSV, suggesting that the neutralizing capacity is
specific to LASV GP (Fig. 5d). We used a guinea pig VSV-polyclonal
antiserum as a control for efficient wild-type VSV neutralization. To
estimate the power of neutralization by VLP immunization, we
compared the neutralization titers of immunized animals with
neutralization titers of human serum samples collected in a highly
LASV-endemic area of Guinea (Fichet-Calvet and Magassouba,
unpublished data). IgG antibodies specific for LASV GP were
Fig. 5 Neutralizing antibody responses elicited by LASV GP VLP immunization. a Serial dilutions of day 77 sera from VLP-immunized
rabbits were incubated with either LASV lineage II (LASV/NGA/2018/IRR/015) or LASV lineage IV (Josiah), and Vero 76 cells were infected with
the serum–virus mixture. An unrelated rabbit- or human-derived serum served as negative control, while monoclonal antibody 37.7H served
as positive control. Infected cells were stained with a specific LASV NP antibody and an HRP-labeled secondary antibody. Mean values of
neutralization titer [IC50 values] are plotted with error bars indicating standard deviations. b Breadth of neutralization against five lineages of
LASV. Pseudoviruses generated with clones derived from five LASV lineages and VSV G were assessed for their neutralization sensitivity (50%
neutralization titer [ID50]) to twofold serial dilutions of day 77 sera from Rb#347 and Rb#350, and 37.7H antibody as positive control. Mean
values are plotted with error bars indicating standard deviations. c Serial dilutions of day 77 sera from immunized rabbits, and 37.7H control
antibody were incubated with VSVΔG/LASVGP. Virus neutralization titers were calculated as geometric mean titers (GMT) of the reciprocal
value of the last serum dilution at which inhibition of the cytopathic effect on infected Vero E6 cells was detectable. Pre-immune sera
(D0 samples) from corresponding rabbits were used as controls. The initial dilution was 1:16 and was therefore denoted as a titer of eight for
GMT calculation. Graphs represent the means from three independent experiments. Error bars indicate standard deviations. d Infectivity of
wild-type VSV was determined in the presence of D77 serum samples. Polyclonal neutralizing antibodies against VSV were used as a positive
control. e LASV GP IgG ELISA. A total of 37 human serum samples collected in an LASV-endemic area of Guinea were analyzed at 1:200 dilution
for the detection of IgG antibodies against LASV GP. The mean of OD 450 nm values (duplicate measurement) are shown. The dashed line
depicts the cut-off for a positive antibody response, calculated as the mean of human negative sera+ twofold SD. A standard curve was
prepared using the human monoclonal antibody 37.7H. Graphs represent the means from four independent experiments. Error bars indicate
standard deviations. f Human sera were tested for neutralizing antibodies against LASV GP using VSVΔG/LASVGP. VSV expressing wild-type
glycoprotein G was used as a control. Virus neutralization titers were calculated as GMT and the mean value of all measurements is shown.
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determined using a LASV GP ELISA (Fig. 5e). From a total
37 samples, 21 samples were reactive against LASV GP, while
16 samples were LASV GP seronegative. We then tested these
samples for their neutralizing activities. Mean neutralization titers
for all LASV GP seronegative sera were 1:10. The GP seropositive
sera neutralized VSVΔG/LASVGP infection with a mean titer of 1:92
(Fig. 5e). No unspecific neutralizing effects were observed using
wild-type VSV. These results indicate that the GP VLP immuniza-
tion was superior in eliciting nAb responses compared with
human serum samples that are IgG-positive for antibodies to LASV
GP. Overall, these results show that the VLPs were capable of
inducing GP-specific antibodies that effectively neutralize LASV.
Induction of nAb titers requires several immunizations
We next wanted to determine the kinetics of nAb development
against LASV GP. Therefore, we assessed the neutralizing activity
of sera collected at day 0, day 28, day 49, day 70, and day 77 of the
prime-boost immunization regimen. Both animals developed low
levels of nAb activity 4 weeks after priming, while repeated
boosting substantially increased nAb titers (Fig. 6a). These data
illustrate that repeated immunization of GP is required for efficient
induction of functional nAbs. The increase in neutralizing activity
correlated with the IgG ELISA results using recombinantly
expressed GP1 and GP2 proteins, showing a continuous increase
of GP-binding antibodies over the course of immunization
(Fig. 6b). In addition, we performed immunofluorescence micro-
scopy analysis using the stably transfected LASV GP MDCK II cell
line to test whether the rabbit immune sera collected at the early
time points post-priming recognize GP molecules expressed on
the cell surface. GP expression was confirmed using the positive
control sera α231 and α3. In contrast, cells that were immunos-
tained with a negative control serum or the pre-immune sera
(D0 samples) from immunized animals did not show any GP-
specific signals. Consistent with our neutralization and ELISA data,
all tested immune sera, including those from the early time points
post-priming, have antibodies capable of recognizing GP (Fig. 6c).
Fig. 6 Induction of robust neutralizing antibody titers requires several immunizations. a Geometric mean neutralizing antibody titers
against VSVΔG/LASVGP at 0, 28, 49, 70, and 77 days are shown (n= 1). The initial dilution was 1:16 and was therefore denoted as a titer of
eight for GMT calculation. b ELISA of total IgG response against LASV GP1 or GP2 of 1:200 dilution of rabbit sera collected at indicated time
points is shown. Error bars are representative of the SD of OD 450 nm values (duplicate measurement of two independent experiments). The
cut-off for a positive antibody response is indicated as a dashed line, calculated as the median of the pre-immune sera (D0)+ 10%.
c Immunofluorescence microscopy using MDCK II cells stably expressing LASV GP demonstrates the recognition of GP by serum antibodies
collected from immunized rabbits at indicated time points post-priming. An unrelated rabbit serum was used as a negative control, while
α231 and α3 were used as a positive control. All sera were diluted 1:200. Anti-rabbit Alexa Fluor 568 was used as a secondary antibody, and
nuclei were visualized by DAPI staining. Merged images of GP and nuclear staining are shown. Scale bars, 200 µm.
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Mechanism of neutralization by polyclonal nAbs
nAbs may prevent virus infection either through blocking the
attachment to host cell receptors or by interfering with postbind-
ing events, such as internalization or viral fusion during entry. To
address this, we performed pre- and postattachment neutraliza-
tion assays. Antisera Rb#347_D77 and Rb#350_D77 were incu-
bated with VSVΔG/LASVGP before or after virus binding to Vero E6
cells, and infection was measured by western blot analysis. As
expected, both antibody preparations efficiently neutralized
infection in a dose-dependent manner when preincubated with
VSVΔG/LASVGP (Fig. 7a, b, upper panel). To determine the ability
of the antibodies to neutralize infection at a postattachment step,
VSVΔG/LASVGP was allowed to bind to Vero E6 cell monolayers at
4 °C for 1 h. Serially diluted polyclonal rabbit immune sera were
then added to determine if they can prevent the attached virus
from infecting Vero E6 cells. While we observed no neutralizing
activity for antiserum Rb#347_D77, antiserum Rb#350_D77
efficiently inhibited VSVΔG/LASVGP infection in a dose-
dependent manner when added after virus adsorption to the cell
surface, suggesting that at least part of its neutralizing activity
occurs at a postattachment step (Fig. 7a, b, lower panel). An
unrelated rabbit control serum showed no inhibitory effect on
VSVΔG/LASVGP infection in our pre- and postattachment neu-
tralization assays (data not shown).
Purification of IgG with high recovery of neutralizing activity
We purified rabbit IgG from the antisera using a protein A affinity
column strategy and tested whether it retained functional activity.
IgG purity and possible residual serum protein contaminations
were assessed using SDS-PAGE followed by SYPRO Ruby protein
gel staining. Figure 8a demonstrates that IgG purification yielded
high levels of intact and pure IgGs for both rabbit serum samples
(designated Rb#347_D77+ and Rb#350_D77+), with protein
concentrations ranging from 1.23 to 7.91 mg/ml. We then
assessed the ability of affinity-purified IgGs to bind to GP and to
neutralize GP-mediated virus entry to shed light on changes in GP-
specific IgG binding titers and measure the functional quality of
the recovered IgGs. The neutralizing activity of the purified IgG
preparations against VSVΔG/LASVGP was increased compared
with the untreated serum samples, with geometric mean titers
(GMTs) ranging from 1:1280 to 1:3072 (Fig. 8b). Consistent with
the increase in nAb activity, ELISA results of purified rabbit IgG
samples showed elevated binding reactivity against GP1 and GP2
over prepurified serum samples (Fig. 8c). In summary, these results
demonstrate that the neutralizing properties of anti-GP IgGs were
successfully recovered following protein A IgG purification.
VLP-induced nAbs inhibit LASV GP-mediated infection of human
target cells
LASV infects various cell types in vitro and in vivo, including
monocyte-derived macrophages and dendritic cells and liver
epithelial cells. The use of multiple cellular receptors likely
contributes to the broad host cell tropism of LASV10,52. We finally
aimed to evaluate the potential of the anti-LASV polyclonal
antibody preparations to inhibit the infection of relevant human
target cells using human hepatoma epithelial (HuH7) cells as well
as differentiated THP-1 cells, a human leukemia monocytic cell line
that is widely used to study monocyte/macrophage function53.
Because the morphological characteristics of VSVΔG/LASVGP-
induced cytopathic effects (CPE) varied in these cells and therefore
restricted the microscopic scoring and comparison of the CPE-
mediated readout, we employed a flow cytometry-based neu-
tralization assay to circumvent these limitations. Purified IgG
preparations Rb#347_D77+ and Rb#350_D77+ were twofold
diluted, from 1:250 to 1:1000, and then incubated with VSVΔG/
LASVGP (MOI 0.1) at 37 °C for 1 h. Then, the virus–antibody
mixtures were added to the cells. At 22 h post infection, we
measured the percentage of infected cells by flow cytometry
analysis using a guinea pig, VSV-polyclonal antiserum as the
primary antibody, and a rabbit anti-guinea pig secondary antibody
labeled with fluorescein isothiocyanate (FITC). VSVΔG/LASVGP
infection in the absence of neutralizing sera served as a positive
control. All examined cell lines were susceptible to VSVΔG/LASVGP
infection, although the infection efficiencies varied (Fig. 9a, virus
control column). While the percentage of VSVΔG/LASVGP-infected
Vero E6 cells reached 55%, infection of HuH7 and differentiated
THP-1 cells reached 80% and 45%, respectively. Both IgG
preparations efficiently reduced VSVΔG/LASVGP infectivity in all
cell lines tested (Fig. 9a). When we set the virus control for each
cell line to 100%, we observed a dose-dependent neutralizing
effect for both IgG preparations. Similar to our observations
described before, Rb#350_D77+ exhibited a greater neutralization
activity against LASV GP in comparison with Rb#347_D77+
(Fig. 9b). In summary, these results demonstrate that antibodies
induced by LASV GP VLP immunization are capable of neutralizing
the infection of human LASV target cells.
Fig. 7 Mechanism of LASV neutralization. Pre- and postattachment inhibition assays were used to determine the mechanism of
neutralization. Data are shown for D77 samples of Rb#347 (a) and Rb#350 (b). Rabbit sera were serially diluted with an initial dilution of 1:64
and incubated with VSVΔG/LASVGP either before virus attachment (pre) or after virus attachment (post) at the cell surface. Cell lysates were
harvested 24 h post infection and analyzed by SDS-PAGE and western blotting. LASV GPC and GP2 were stained with rabbit α4 and an anti-
rabbit Alexa Fluor 680 as a secondary antibody. Tubulin was used as a loading control.
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DISCUSSION
LF is an acute viral disease associated with severe, life-threatening,
multiple organ failure and hemorrhagic manifestations. The lack of
approved medical countermeasures underscores the necessity of
developing safe and effective therapeutics and vaccines. Passive
immunization experiments of convalescent immunoglobulin
preparations and monoclonal antibodies suggest that antibody-
based therapeutics represent an effective approach for the
treatment of LF. Here, we explored the potential of generating
animal-derived hyperimmune sera using LASV GP expressed on
the surface of VLPs as an immunogen. Our data show that the GP
VLP platform is capable of inducing GP-specific antibody
responses and demonstrate that this immunization approach
can induce broadly nAbs.
The preservation of neutralizing epitopes is important for
ensuring efficient induction of nAbs. The majority of human
monoclonal antibodies that effectively neutralize LASV bind to
quaternary structure epitopes, which are only expressed in the
context of the properly assembled trimeric form of GP41,42. We
employed a MDCK II cell line stably expressing full-length LASV
GPC to generate VLPs that display mature GP spikes47. Similarities
between the ultrastructural organization of the immunogenic
ectodomain of GP on the surface of VLPs and authentic LASV
suggest that VLP-derived GP may be capable of inducing an
antibody response that is comparable with the antibody response
during natural infection49. The robust induction of GP-binding
antibodies elicited by our adjuvanted GP VLP immunization
approach reported here is in line with previous work that
elucidated the immunogenicity of mammalian cell-derived LASV
VLPs based on co-expressed GP and matrix protein Z, or GP, Z, and
NP54. In that study, the ability of these VLPs to induce an immune
response against LASV was evaluated in mice using a prime-boost
immunization schedule in the absence of an adjuvant. However,
the VLPs’ protective effectiveness and capability to induce nAbs
were not investigated. The binding of antibodies to both subunits
GP1 and GP2 measured in our GP subunit-specific ELISA suggests
that the hyperimmune sera may exhibit numerous effects. GP1
mediates binding to host cell receptors, whereas GP2 facilitates
virus–host membrane fusion during entry.
Using authentic LASV and two BSL2 surrogate systems based on
a replication-competent VSV expressing LASV GP and murine
leukemia virus (MLV)-based LASV GP-pseudotyped particles, we
measured significant neutralization activity of the hyperimmune
sera. While we observed low levels of neutralization activity after a
single immunization, nAb titers substantially increased after
boosting. This increase suggests that multiple presentations of
the antigen in its native conformation are required to produce an
efficient nAb response. Immunization with adjuvanted GP VLPs
induced nAb titers that were higher than nAb titers measured in
LASV GP IgG-positive Guinean human serum samples. Convales-
cent blood therapy has been suggested to improve the survival
rate of LF patients. However, high nAb titers and antigenic
matching were required for protection21,34. It will be interesting to
determine whether GP VLPs can induce high titers of nAbs that
are sufficient to give protection against experimental LASV
challenges in animal models. Affinity chromatography methods
using immobilized GP as a ligand may be used to improve the
neutralizing activity of hyperimmune sera-derived antibodies.
The high degree of sequence divergence of LASV genomes is a
major challenge for the development of an effective pan-LASV
vaccine and immunotherapeutic intervention strategies. An ideal
vaccine or antibody-based therapeutic will need to confer protection
against all circulating LASV strains. Currently, LASV strains are
grouped into four established lineages. Lineages I, II, and III circulate
in Nigeria, whereas lineage IV circulates in several other West African
countries including Guinea, Sierra Leone, and Liberia55. In addition,
several putative lineages have been proposed for strains circulating
Fig. 8 Purification and characterization of IgG preparations. a Using protein A affinity chromatography, IgG was isolated from rabbit sera
collected 1 week after the final boost (D77). For IgG purification analysis, 3 μg of total protein from each preparation was separated by SDS-
PAGE and stained with SYPRO Ruby protein gel staining. Lanes 1 and 3: initial antiserum; lanes 2 and 4: elution of protein A affinity
chromatography. b Neutralizing antibody response against VSVΔG/LASVGP of initial antisera (D77 samples) and affinity-purified IgG (D77+
samples). Bars represent the mean, and error bars indicate the standard deviation of GMT values of three independent experiments.
c Detection of α-LASV GP1 or GP2 antibodies using ELISA. The values shown represent the means of the reciprocal serum dilutions. Error bars
are representative of the SD of OD 450 nm values (duplicate measurement of three independent experiments).
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in Mali and Côte d’Ivoire56 (lineage V), Nigeria57 (lineage VI), and
Togo58 (lineage VII). Despite this genetic diversity, some human
monoclonal antibodies with broadly cross-neutralizing activity have
been described41. Using neutralization assays with authentic LASV,
the hyperimmune sera from VLP-immunized animals showed potent
neutralizing activities against the homologous LASV strain Josiah
(lineage IV), and were also capable of cross-neutralizing the infection
of a clinical isolate from lineage II that was recently isolated from an
LASV patient during the 2018 LF outbreak in Nigeria50. As
determined by a pseudotype-based neutralization assay, it is
encouraging that our VLP immunization approach using GP from
the prototypic strain Josiah elicited broadly reactive antibodies
capable of inhibiting virus entry of five different LASV lineages (I–V).
Our results suggest that the VLP immunization elicited antibodies
that bind to conserved epitopes associated with cross-neutralization
of multiple LASV lineages.
Antibodies can block viral infection at various steps during virus
entry. Both rabbit immune sera inhibited virus infection when
preincubated with VSVΔG/LASVGP, suggesting that the serum
antibodies can block the interaction between GP and host cell
surface receptors. In addition, antibodies may also be capable of
blocking infection at a postattachment step. We found that the
antiserum Rb#350 also inhibited VSVΔG/LASVGP infection when
added after virus adsorption to the cell surface, suggesting that
Fig. 9 Inhibition of VSVΔG/LASVGP infection of human cells. Flow cytometry analysis was used to determine the neutralizing capacity of
the IgG preparations to inhibit LASV GP-mediated infection of human cells. HuH7 cells, differentiated THP-1 cells, and, for comparison, Vero E6
cells were infected with VSVΔG/LASVGP after preincubation of the virus with serially diluted IgG preparations. Infection without sera and
untreated cells served as a control. At 22 h post infection, the cells were harvested, fixed, and stained with a polyclonal guinea pig serum
against VSV and an anti-guinea pig antibody labeled with FITC as a secondary antibody. a A representative experiment is shown to illustrate
flow cytometry-based virus neutralization for Rb#347 and Rb#350 using purified IgG preparations at a dilution of 1:250. For all experiments,
living cells were distinguished from cell fragments by FSC-H/SSC-H, referring to cell size and granularity in the starting population. For each
cell line, untreated VSVΔG/LASVGP-infected cells were used as positive controls. Uninfected cells treated with the highest concentration of
each serum were used as negative controls. These cells were then gated in the serum control that was stained only with the FITC-labeled
secondary anti-guinea pig antibody to discriminate between non-infected cells and infected cells (VSVΔG/LASVGP-positive). Percentage of
infected cells among the living cells is indicated. b Quantification of infected cells depended on the serum dilution used. Virus control was set
to 100% for each cell line, and the relative number of infected cells was calculated for each serum dilution. The values shown represent the
mean of two independent experiments.
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part of its neutralizing activity occurs at a postattachment step.
These antibodies may inhibit virus internalization or block the
conformational changes of GP required to mediate fusion with the
host membrane. For example, structural analyses revealed that the
human monoclonal nAb 37.7H neutralizes LASV by stabilizing GP
in the prefusion conformation, thereby inhibiting the conforma-
tional changes required for intracellular LAMP1 binding and
subsequent virus fusion42. Structure-based epitope mapping of
polyclonal antibodies elicited by LASV GP VLP immunization may
help to elucidate the mechanisms underlying GP binding and
neutralization59. Furthermore, using HuH7 cells and differentiated
THP-1 cells as representative cell culture models, we found that
the rabbit immune sera were able to inhibit in vitro virus infection
of human epithelial liver cells and macrophages. Particularly,
immune cells are the early target cells of human LASV infection60.
Therefore, our VLP-elicited antibodies may have the potential to
block virus dissemination in vivo by inhibiting virus replication at
the early stage of the disease.
We show an extensive nAb response here despite the use of
fully glycosylated GP as an immunogen. These results were
somewhat unexpected because previous studies have suggested
that the native GP is a poor immunogen for efficiently inducing
nAbs18,26. This poor outcome has been attributed to the presence
of an extensive glycan shield19. Studies in mice have shown that
changes in the number of N-glycans alter viral neutralization
sensitivity from resistant to potently neutralizing18. Although the
removal of individual N-glycans improved the immunogenicity
and induction of nAbs, the contribution of N-glycans to GP folding
and maturation makes them critical components for the induction
of a biologically relevant GP-specific antibody response15,
suggesting that the native glycosylation profile may be needed
for the effective induction of nAbs.
Passive antibody therapy has long been used in the treatment
and postexposure prophylaxis of various diseases, including viral
infections and the development of heterologous polyclonal
antibody preparations obtained from hyperimmunized animals
against several highly pathogenic viruses such as Ebola, Junín, and
Nipah40,46,61,62. Our VLP-based approach combines several advan-
tages for therapeutic antibody production. VLPs morphologically
resemble authentic virions that display antigens in their native
conformation in a highly ordered and repetitive manner capable
of inducing strong immune responses63. Most human antibodies
that neutralize LASV bind to quaternary structure epitopes
containing regions from both GP1 and GP2. LASV VLPs display a
correctly folded and conformationally relevant GP, which means
that they have advantages over GP-subunit vaccines that lack
higher-order protein structures and epitopes displayed on the
intact virus64,65. As hyperimmunized serum contains a mixed
population of antibodies, polyclonal antibody preparations can
bind and neutralize multiple epitopes on GP, which may also
reduce the emergence of viral escape mutants. VLPs do not
contain a viral genome, so they are not replication competent and
therefore not infectious. Therefore, VLPs do not need to be
inactivated during the manufacturing process, which may
compromise vaccine efficacy due to potential effects on protein
structure and conformational epitopes. Furthermore, in the case of
newly emerging, phylogenetically, and antigenically distinct LASV,
cell culture-based GP VLPs can be rapidly generated based on
available sequence information as antigens and animal-derived
polyclonal antisera can be produced in scalable quantities. Thus,
hyperimmune sera or hyperimmune immunoglobulin prepara-
tions are an attractive alternative to human monoclonal anti-
bodies isolated from LF survivors in the early phase of an outbreak
when convalescent donor material may not be readily available.
Rabbit-derived immunoglobulin preparations are used for the
treatment of certain conditions and are, in general, well tolerated.
For example, rabbit-derived antithymocyte globulin is licensed for
clinical use for the prevention and treatment of acute rejection in
organ transplantation66.
Several vaccines under development against emerging viruses
are based on the VLP platform67, providing a rationale for the use
of LASV GP-derived VLPs as a vaccine candidate. An effective
vaccine against LASV is likely to require the induction of robust
antibody and T-cell responses. We demonstrate that GP VLPs
induced robust nAb responses in rabbits, yet their capacity to
induce efficient cellular responses and cell-mediated protection
against LASV remains to be determined. In general, the good
safety profile makes VLP-based vaccines an appropriate choice for
children, immunocompromised individuals, and pregnant women.
The WHO has identified pregnant women as a primary target
population for LASV vaccination, because LF is particularly severe
in pregnancy, with high rates of maternal and fetal death68.
Our study has several limitations. We used the Sigma Adjuvant
System as an immunostimulant, but we did not investigate the
immunogenicity of GP VLPs and the induction of nAbs in the
absence of an adjuvant. Nor did we assess the capacity of other
adjuvants to enhance the antibody response. Alternative adjuvant
formulations may have the potential to induce a more vigorous
production of LASV-nAbs. Future studies are needed to explore
the effectiveness of different adjuvant systems systematically69,70.
Such data will guide the selection of an optimal adjuvant
formulation for GP VLP-based immunization strategies. Passive
transfer of human monoclonal neutralizing anti-GP antibodies
confers protection against LF in animal models37,71. While our
results indicate that the GP-derived VLPs described in this study
are potent at inducing nAbs against LASV, future studies need to
evaluate their therapeutic efficacy in animal models. Furthermore,
we have used canine cells to generate LASV GP VLPs to ensure
structurally authentic mammalian glycosylation. Our enzymatic
deglycosylation assays revealed a glycosylation pattern of VLP-
derived GP similar to that of naturally occurring LASV virions
released from human and rodent cells. While the N-linked glycan
biosynthesis processing pathway is highly conserved across
mammalian cell types, species-specific variations exist that may
influence the immunogenicity of the target antigen. Current
research efforts address the use of human cell lines for GP VLP
manufacture because only human cell lines can produce proteins
that contain posttranslational modifications (PTMs) similar to
those seen in humans72. Using human cell lines would offer the
advantage of producing a human-specific glycosylation pattern of
PTMs, as compared with those produced in animal cell lines.
In conclusion, our results demonstrated that LASV GP-induced
VLPs in combination with a squalene-based adjuvant formulation
were immunoreactive in an animal model and capable of inducing
potent broadly nAb responses. These data warrant further
research of heterologous animal-derived hyperimmune sera as a
potential treatment option against highly pathogenic LASV.
METHODS
Cells, plasmids, and viruses
African green monkey kidney cells (Vero E6, ATCC CRL-1586) and human
hepatoma cells (HuH7, ATCC CCL-185) were maintained in Dulbecco’s
modified Eagle’s medium (DMEM, Sigma-Aldrich). MDCK II cells (ATCC CCL-
34) were maintained in modified Eagle’s medium (MEM, Sigma-Aldrich).
Each medium was supplemented with 10% (v/v) fetal bovine serum (FBS,
Invitrogen), 2 mM L-glutamine (Sigma-Aldrich), and 50 U/ml penicillin and
50 µg/ml streptomycin (Sigma-Aldrich). Human embryonic kidney 293T
(HEK293T, ECACC 12022001) cells were grown in Dulbecco’s modified
essential medium (Invitrogen) supplemented with 10% FBS and 0.1 mM
nonessential amino acids (NEAA, Gibco). Baby hamster kidney cells
(CVCL_1915) were maintained in Glasgow’s MEM (Gibco) supplemented
with 10% (v/v) newborn calf serum (Gibco), 2 mM L-glutamine (Sigma-
Aldrich), 50 U/ml penicillin and 50 µg/ml streptomycin (Sigma-Aldrich), 1 ×
NEAA (Gibco), and 5% tryptose phosphate broth (Gibco). The THP-1 cells
(ATCC-TIB-202) were maintained in RPMI 1640 medium (PanBiotech)
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supplemented with 10% FBS and 2mM L-glutamine, 50 U/ml penicillin and
50 µg/ml streptomycin, and 1 × NEAA and sodium pyruvate (Gibco). THP-1
cells (4 × 105/well) were differentiated using 200 nM phorbol 12-myristate
13-acetate (PMA, Sigma-Aldrich)73. PMA was removed after 2 days of
treatment. Cells were then grown for an additional 5 days in supplemented
RPMI 1640. All cell cultures were grown under standard conditions in a
humidified 37 °C, 5% CO2 incubator.
For vectorial expression of arenavirus GPs in eukaryotic cells, we used
the mammalian expression vector pCAGGS74. The pCAGGS plasmid
encoding the ORF of full-length GPC of LASV strain Josiah (GenBank
NC_004296, lineage IV) and LCMV strain WE (GenBank AAA46265),
respectively, were described earlier47,75. The ORF of LASV Togo GPC
(GenBank LT601602, lineage VII76) was amplified from viral RNA using
reverse transcription (RT)-PCR and cloned into pCAGGS. The GPC ORFs of
LASV strain Pinneo (GenBank KM822128, lineage I), LASV strain 803213
(GenBank AF181854, lineage II), and LASV strain AV (GenBank AF246121,
lineage V) were commercially synthesized (BaseClear B.V., The Netherlands)
and cloned into pCAGGS. The sequences of the GP ORFs were confirmed
by DNA sequencing. Vero E6 cells were transfected using TransIT-LT1
(Mirus) according to the manufacturer’s protocol.
For LASV stock production, the LASV strain Josiah (GenBank AY628203)
and the LASV human clinical isolate LASV/NGA/2018/IRR/015 (GenBank
MK117963)50 were grown on Vero cells. Viral titers were determined by an
immunofocus assay, or by defining the 50% tissue culture infectious dose
(TCID50).
For immunofocus assay, Vero cells in 24-well plates were inoculated with
200 µl of serial tenfold dilutions of LASV. After 1 h, the inoculum was
removed and 1%-methylcellulose medium overlay was added. The cells
were incubated for 5 days and then fixed with 4% formaldehyde,
permeabilized with 0.5% Triton X-100, and blocked with 10% FCS. Cell foci
were detected with LASV NP-specific mouse monoclonal antibody 2F1 and
a peroxidase-labeled anti-mouse IgG as secondary antibody. Foci were
visualized with tetramethylbenzidine and counted77. For TCID50 assay, Vero
cells were grown in 96-well plates to 60% confluence. Cells were
inoculated with tenfold serial dilutions of supernatant from LASV-
infected Vero cells. The assay was evaluated at 7–9 days post infection.
TCID50 values were calculated using the Reed–Muench method
78. All
experiments with infectious LASV were performed in the BSL4 facilities at
the Institute of Virology of the Philipps-University Marburg, Marburg, and
the Bernhard-Nocht Institute for Tropical Medicine, Hamburg, in com-
pliance with German regulations.
The recombinant VSV expressing the GPC derived from LASV strain
Josiah in place of the original VSV G (VSVΔG/LASVGP) was grown in Vero
E6 cells79. The viral titer of VSVΔG/LASVGP was determined by plaque
assay using an Avicel RC-591 overlay. The day before the assay, 3.3 × 105
Vero E6 cells/well were seeded and cultivated until reaching a confluence
of 100%. Tenfold serial virus dilutions in DMEM without FBS were
performed and 400 µl/well were added to the cells in 12-well tissue culture
plates. For the overlay, 2.4% Avicel in phosphate-buffered saline (PBS)
buffer solution was mixed with an equal volume of MEM with 4% FBS and
4mM L-glutamine, 100 U/ml penicillin, and 100 µg/ml streptomycin. After
incubation for 1 h at RT with gentle agitation, 800 µl/well of 1.2% Avicel
overlay were added, and the cells were incubated at 37 °C for 48 h. To fix
the cells, the Avicel overlay was aspirated and 10% formaldehyde solution
containing 0.1% (w/v) crystal violet was added and incubated for 30min at
RT. Viral titers were expressed as plaque-forming units (PFU).
For the generation of pseudotype viruses, five GPC constructs (all in the
pCAGGS expression plasmid) representing five different LASV lineages
were used. The LASV GPCs used were: lineage I, LASV/LP/NIG/69/H,
GenBank AF181853; lineage II, LASV/803213/NIG/74/H, GenBank AF181854;
lineage III, LASV/GA391/NIG/74/H, GenBank X52400; lineage IV, Josiah,
GenBank NP_694870; and lineage V, LASV/AV/IC, GenBank AF246121. The
MLV Gag-Pol packaging vector (phCMV-5349) and luciferase encoding
reporter plasmid (pTG126) have been reported previously80. All plasmids
were grown and purified using endotoxin-free GeneluteTM HP Midiprep
kits (Sigma). DNA quality was assessed by agarose gel electrophoresis and
quantified by spectrophotometry at 260/280 nm using a Nanodrop
(Thermo). LASVpv were generated based on previously described
protocols80. Briefly, 1.5 × 106 HEK293T cells were seeded overnight in a
10 cm diameter Primaria-coated dish (Corning). Transfections were
performed with 2 µg each of the MLV Gag-Pol packaging vector, luciferase
reporter plasmid, and plasmid-encoding LASV GPC using 24 µl cationic
polymer transfection reagent (polyethylenimine), in the presence of
Optimem (Gibco), and the media replaced with 10ml complete DMEM
after 6 h. A no-envelope control (empty pseudovirus) was used as a
negative control in all experiments. Supernatants containing LASVpv were
harvested at 72 h post transfection and filtered through 0.45-μm-pore-size
membranes. The generated LASVpv can achieve a single-round infection in
HuH7 target cells and contains a luciferase reporter gene that can be
expressed in infected cells.
Antibodies
LASV GP subunits were detected using the monoclonal mouse antibody,
designated AC1, specific for the GP1 subunit (kindly provided by M.C.
Georges-Courbot, Unit of Biology of Viral Emerging Infections, Institute
Pasteur, Lyon, France), a monoclonal human antibody designated 37.7H
(absolute antibody) or polyclonal antibodies raised in rabbits: α231
recognizing the C-terminal GP1 domain, α3 recognizing the N-terminal
GP2 ectodomain, and α4 detecting the cytoplasmic domain of GP281,82. A
mouse monoclonal anti-LASV nucleoprotein NP antibody, designated 2F1,
was used for the detection of infected foci by immune focus assays77.
Guinea pig VSV-polyclonal antiserum was kindly provided by W. Garten
(Institute of Virology, Marburg, Germany). Mouse monoclonal tubulin
antibody was obtained from SIGMA Life Science. For western blot analysis,
an anti-rabbit secondary antibody labeled with Alexa Fluor 680 (Invitrogen)
and an anti-mouse secondary antibody labeled with Alexa Fluor Plus 800
(Invitrogen) was used. Anti-rabbit secondary antibodies labeled with Alexa
Fluor 568 or 488 (both from Invitrogen) were used for immunofluorescence
staining and a secondary antibody labeled with horseradish peroxidase
(HRP, DAKO) was used for IPMA and indirect ELISA. An anti-human
secondary antibody labeled with FITC (DAKO) was used for immunofluor-
escence staining. An anti-guinea pig secondary antibody labeled with FITC
(DAKO) was used for flow cytometry staining. An anti-mouse secondary
antibody labeled with HRP (Jackson Immuno Research Laboratories) was
used for immune focus assays.
Human serum samples
Guinean human sera were collected in a highly LASV-endemic area of
Guinea in 2014 by venipuncture from healthy individuals (≥18 years) after
written informed consent was obtained (Fichet-Calvet and Magassouba,
unpublished data). Approval for the investigation was obtained from the
National Ethics Commission of Guinea (permit no. 12/CNERS/12). A total of
96 European human serum samples from healthy anonymous donors were
used to confirm specificity of the LASV GP IgG ELISA.
Production of VLPs
The generation of MDCK II cell lines stably expressing LASV GP has been
described previously47. For production of GP-derived VLPs, MDCK II LASV GP
stable cell lines were seeded in 175 cm2 tissue culture flasks and cultured at
37 °C for 4 days. After reaching a confluence of 100%, the medium were
replaced by MEM supplemented with 2% FBS, 2mM L-glutamine, and 50 U/
ml penicillin and 50 µg/ml streptomycin, and the cells were incubated for an
additional 4 days. Culture supernatants were harvested and clarified twice by
centrifugation at 3345 × g for 10min at 4 °C. VLPs were then pelleted by
ultracentrifugation through a 20% (w/v) sucrose cushion for 1.5 h at
110,000 × g and 4 °C. The pellets containing VLPs were resuspended in
sterile PBS and stored at 4 °C. The VLPs were freshly prepared prior to each
immunization. VLP preparations used for western blot analysis or electron
microscopy (EM) were stored at −80 °C until further analysis. The total
protein concentration of the VLP preparations was 2.2 ± 0.2mg/ml, as
determined by a Pierce BCA Protein Assay kit with a bovine serum albumin
(BSA) standard (Thermo Scientific).
Treatment with endoglycosidases
MDCK II LASV GP cells, or MDCK II cells, HuH7 cells, and BHK cells infected
with LASV Josiah at a multiplicity of infection (MOI) of 0.1 were incubated
for 5 days. Cell culture supernatants were clarified by low centrifugation at
3345 × g for 10 min at 4 °C. VLPs and virus particles were then harvested by
ultracentrifugation through a 20% (w/v) sucrose cushion for 1.5 h at
110,000 × g and 4 °C. The pellets containing GP VLPs or LASV virions were
resuspended in sterile PBS, followed by the addition of a reducing SDS
sample buffer. Samples were treated with either EndoH (New England
Biolabs) or N-glycosidase F (PNGaseF, New England Biolabs) according to
the instructions of the manufacturer or left untreated. Samples were
analyzed by SDS-PAGE and western blot analysis.
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SDS-PAGE and western blot analysis
For verification of sample quality and purity, 0.4 µg recombinant LASV GP1
and GP2 proteins and IgG purified from rabbit blood (3 µg of total protein)
were separated by SDS-PAGE using 12% polyacrylamide gels and stained
with SYPRO Ruby protein gel staining (Invitrogen) according to the
manufacturer’s instructions. Samples were analyzed using the ChemiDoc
Imaging System (Bio-Rad). The cell lysates of MDCK II cells and MDCK II
cells stably expressing LASV GPC, as well as purified VLP and authentic
LASV virion preparations, were separated by SDS-PAGE using 12%
polyacrylamide gels and transferred to nitrocellulose blotting membranes
(GE Healthcare Life Science) for western blot analysis. The Odyssey Infrared
Imaging System (LI-COR Biosciences) was used for visualization and
quantification of detected proteins. All gels/blots were derived from the
same experiment and were processed in parallel. In case several gels were
used to fit all samples, they all derive from the same experiment and were
processed in parallel. Uncropped images of the original gels/blots are
presented in the Supplementary Information.
Immunofluorescence assays
A total of 6 × 104 Vero E6 cells/well were seeded on coverslips and
transfected with 1 µg pCAGGS expression plasmids encoding various Old
World arenavirus GPs, and 4.7 × 104 MDCK II cells stably expressing LASV
GP were seeded on coverslips and cultivated until reaching a confluence of
80%. Expression of GP was analyzed 24 h post transfection in Vero E6 cells
and 24 h post seeding in MDCK II LASV GP cells. For the staining of fixed
antigens, the medium were aspirated and cells were incubated with 4%
PFA for 20min at RT and then incubated with 0.1 M glycine for 10min at
RT. Before primary antibody incubation, the cells were permeabilized with
0.1% Triton X-100 for 10min, and nonspecific sites of antibody adsorption
were blocked with 0.2% BSA (Aurion) solution for 20min at RT. For the
staining of unfixed antigens, cell culture medium were aspirated, and the
cells were incubated with the primary antibody. Then, the cells were fixed
with 4% PFA for 20min at RT, incubated with 0.1 M glycine for 10min, and
finally permeabilized with 0.1% Triton X-100 for 10min at RT. LASV GP was
stained with primary rabbit antibodies diluted 1:100 or 1:200 in PBS and
incubated for 1 h at RT. An anti-rabbit antibody conjugated with Alexa
Fluor 488 or 568 was used as a secondary antibody. Cell nuclei were
stained with 0.5 µg/ml 4′,6-diamidino-2-phenylindole (DAPI, Invitrogen).
Finally, cells were washed three times with PBS and subsequently mounted
in Fluoroshield (Sigma-Aldrich) for imaging. Images were taken on a Leica
confocal microscope or with Zeiss Axiovert 200M with ×63 objectives.
Image processing was performed using Fiji ImageJ software.
Electron microscopy
Transmission EM was performed with purified GP VLPs after fixation with
1% PFA for 1 h. VLP suspension was applied to formvar-coated nickel grids
and incubated for 10min. After brief washing in PBS, the samples were
negatively stained with 2% phosphotungstic acid. For on-section immuno-
EM, stable transfected and nontransfected MDCK II cells were slowly grown
in a six-well tissue culture plate until reaching a confluence of 100% and
fixed at a final concentration of 0.1% glutaraldehyde and 2% formaldehyde
by addition of double-strength fixative to the growth medium. The cells
were pelleted, treated with 0.25% tannic acid, and further fixed with 1%
osmium tetroxide containing 1.5% ferricyanide. Pellets were dehydrated in
a graded ethanol series and infiltrated with LR White containing 2%
benzoyl peroxide at 4 °C, followed by polymerization at 53 °C for 24 h in
gelatin capsules. Ultrathin sections of 70 nm were collected on formvar/
carbon-coated nickel grids. For immunogold labeling, the sections were
blocked in 1% BSA in PBS and then incubated for 1 h with rabbit sera
Rb#347_D77 and Rb#350_D77, respectively, diluted 1:20 in PBS containing
1% BSA. After washing with PBS, the grids were incubated for 1 h in
protein A conjugated to colloidal gold (PAG 6 nm, Aurion), washed with
PBS, treated with 0.25% glutaraldehyde, washed with water, and finally air-
dried. All electron micrographs were acquired using a JEOL JEM1400 with a
TVIPS TemCam F416 camera.
Immunization
All animal experiments were carried out in compliance with the regulations
of German animal protection laws and authorized by the Regierung-
spräsidium Darmstadt, Germany. New Zealand White rabbits (Oryctolagus
cuniculus) were purchased from Charles River Germany. For generation of
rabbit LASV antisera, animals were immunized intramuscularly with 300 µg
of LASV GP VLPs mixed in a 1:1 ratio (v/v) with Sigma Adjuvant System, and
boosted 4, 7, and 10 weeks later. Blood samples were collected before
each boost from the marginal ear vein on days 0, 28, 49, and 70, and
animals were sacrificed 77 days post immunization by exsanguination.
Antisera purification
Total IgG was purified from rabbit antisera using the Antibody Serum
Purification Kit (Protein A) from Abcam according to the manufacturer’s
instructions. The antibody concentration was determined using a Pierce
BCA Protein Assay kit with a BSA standard (Thermo Scientific) and
measured in a NanoPhotometer NP80 (Implen). The purity of IgG
preparations was assessed by 12% SDS-PAGE and SYPRO Ruby protein
gel staining (Invitrogen).
Quantification of total IgG antibodies by IPMA
For determination of LASV GP-specific antibodies by IPMA, 2 × 102 Vero E6
cells/well were seeded in 96-well tissue culture plates and infected with
800 PFU/well of VSVΔG/LASVGP, or with the same amount of DMEM as a
control. Cells were incubated for 24 h at 37 °C before fixation with 4% PFA
and permeabilized with 0.1% Triton X-100. Serial twofold dilutions of an
initial 1:16 dilution of immunized rabbit antisera or LASV GP-specific
polyclonal antibodies α4 as a positive control were added to the fixed cells
and incubated for 1 h at RT, followed by incubation with an HRP-coupled
secondary antibody, and visualized by staining with TrueBlue (KPL). Total
antibody titers were calculated as a mean of the reciprocal value of the last
serum dilution at which positive staining was detected from three
independent experiments.
Quantification of total IgG antibodies by ELISA
Total IgG antibody responses against LASV GP in human serum samples
were determined by ELISA. Briefly, high binding ELISA microtiter plates
(Greiner Bio-One) were coated with 2.5 µg/ml of purified LASV GP VLPs and
incubated for 20 h. Following washing in PBS/0.1% Tween20 (PBST) and
blocking (PBS/5% milk powder), 1:200 dilutions of serum sample were
added to the plates and incubated for 1 h. Polyclonal-HRP antibody
(1:1000, DAKO) in conjunction with TMB substrate (KPL) was used to
develop the reaction. OD was determined at 450–650 nm (Synergy H1
Multi-Mode Microplate Reader, BioTek). Each sample was analyzed in
duplicate and the mean OD value of the mock preparation was subtracted.
A standard curve generated from human monoclonal antibody 37.7H was
included with each measurement. The cut-off was calculated as the mean
plus twofold standard deviation of the value of 96 negative human plasma
samples from healthy German blood donors, and the total antibody titers
were expressed as OD 450 nm.
Total IgG antibody responses against LASV GP in rabbit immune sera
were determined by ELISA using recombinant GP1 and GP2 of LASV strain
GA391 (The Native Antigen Company) with human Fc-tag were for coating.
The recombinant proteins were diluted in sterile PBS, and ELISA microtiter
plates were coated with a 2.5 µg/ml protein solution. Antisera from
immunized rabbits, or anti-GP α231 and α3 antibodies as positive controls,
were added at the respective dilution and detected by a polyclonal anti-
rabbit HRP-coupled secondary antibody (DAKO). After staining with TMB
(KPL) for 10min and addition of the stop solution (KPL), the OD was
measured at 450 nm (Epoch Microplate Spectrophotometer, BioTek). Each
sample was analyzed in duplicate, and the mean OD values of three
independent measurements were determined. The cut-off was calculated
as the mean plus 10% of the value of naïve rabbit sera, and the total
antibody titers were expressed as OD 450 nm. Statistical analysis was
performed using GraphPad Prism software version 8. Statistical significance
was calculated using an unpaired t-test (*p value < 0.05).
Neutralization assay using authentic LASV
Immunofocus reduction neutralization assays were carried out to
determine the functional activity of antibodies against authentic LASV
(LASV Josiah, lineage IV or LASV/NGA/2018/IRR/015, lineage II) under
biosafety level 4 containment conditions. Therefore, Vero 76 cells were
seeded in 96-well plates at a density of 12,000 cells/well 1 day before the
neutralization assays. Rabbit antisera were complement inactivated for
30min at 56 °C and diluted in a twofold dilution series with a starting
dilution of 22. Diluted sera, or monoclonal antibody 37.7H as positive
control (initial concentration of 125 µg/ml), were mixed with 1200 FFU
virus and incubated for 60min at 37 °C. Cell culture supernatant was
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removed, and 50 µl of the antibody–virus mixtures were added for 60min
at 37 °C to the cells. After this, the inoculum was removed and 200 µl of 1%
methylcellulose overlay medium were added. At 24 h post infection, the
overlay medium were removed, and the cells were fixed in 4%
formaldehyde in PBS for 30min. After permeabilization with 0.5% Triton-
X-100 for 20min and blocking with 2% FCS in PBS for 30min, the infected
cells were visualized through staining with a mouse anti-LASV NP antibody,
followed by incubation with an anti-mouse HRP-labeled secondary
antibody and TMB. Spots were counted using an ELISpot reader (AID
ELISpot Reader Version 7.0). IC50 values were calculated with a sigmoidal
4PL regression model using GraphPad Prism 8 software.
Neutralization assay using VSVΔG/LASVGP
Replication-competent VSVΔG/LASVGP was used as a surrogate model
system to study LASV neutralization under biosafety level 2 containment
conditions. Complement-inactivated sera, or monoclonal antibody 37.7H
as positive control (initial concentration of 62.5 µg/ml), were serially
diluted, from 23 to 215, in 96-well tissue culture plates. Then, 25 PFU of
VSVΔG/LASVGP were added to the serum dilutions, and after incubation
for 1 h at 37 °C, the virus–antibody mixtures were added to confluent Vero
E6 cells. The cytopathic effect (CPE) was evaluated 2 days after infection.
Neutralization is defined as the reduction of CPE in serum dilutions
compared with CPE in virus controls. Neutralization titers were calculated
as GMTs of four replicates (reciprocal value).
Pseudotype-based virus neutralization assay
For infectivity and neutralization testing of LASV pseudotypes, 1.5 × 104
HuH7 cells/well were plated in white 96-well tissue culture plates and
incubated overnight at 37 °C. The following day, LASV pseudotypes were
mixed with appropriate amounts of heat-inactivated sera or monoclonal
antibody 37.7H as positive control (initial concentration of 50 µg/ml) and
then incubated for 1 h at RT before being added to HuH7 cells for 4 h.
Following this, sera and media were discarded, and 200 µl DMEM were
added to the cells. After 72 h, the medium were discarded, and cells were
lysed with cell lysis buffer (Promega) and placed on a rocker for 15min.
Luciferase activity was then measured in relative light units using a
FLUOstar Omega plate reader (BMG Labtech) with MARS software. Each
sample was tested in triplicate. Neutralizing activities were reported as the
serum dilution level corresponding to 50% inhibitory dilution (ID50) values
and were calculated by nonlinear regression (GraphPad Prism version 8),
using lower and upper bounds (0 and 100% inhibition) as constraints to
assist curve fitting.
Flow cytometry-based virus neutralization assay
For the flow cytometry-based neutralization test, 4 × 105 cells/well of Vero E6,
HuH7, and differentiated THP-1 cells were seeded in six-well tissue culture
plates. Purified IgG preparations (Rb#347_D77+ and Rb#350_D77+) were
serially diluted from 1:250 to 1:1000, and incubated for 1 h at 37 °C with an
equal volume of VSVΔG/LASVGP using an MOI of 0.1. The virus–antibody
mixture was added to the cell monolayers for 22 h. Untreated VSVΔG/
LASVGP-infected cells were used as virus controls. Cells were gently
harvested by trypsinization, fixed with 4% PFA for 20min at RT, and
permeabilized with FACS buffer (PBS, 3% FBS, 2mM EDTA, 0.001% sodium
azide) supplemented with 0.5% saponin for 30min at RT. Samples were
incubated with guinea pig VSV-polyclonal antiserum at a dilution of 1:1000
and then with an anti-guinea pig secondary antibody labeled with FITC at a
dilution of 1:1000 for 1 h at 4 °C each. After each incubation step, cells were
washed twice with FACS buffer and finally subjected to flow cytometry
analysis. Cells were analyzed with BD FACSCalibur, and data sets were
evaluated using the FlowJo v10.0 software package.
Pre- and postattachment assay
Functional characterization of neutralizing activity was determined by virus
neutralization assay using VSVΔG/LASVGP and subsequent western blot
analysis. For preattachment neutralization, the rabbit immune sera were
serially diluted from 26 to 211, and 300 PFU units of the virus were added to
each serum dilution. Following incubation at 4 °C for 1 h, the mixture was
added to Vero E6 cells in a 12-well tissue culture plate and incubated for
1 h at 4 °C. After a further incubation at 37 °C for 1 h, the inoculum was
removed and replaced by DMEM with 2% FBS. For postattachment
neutralization, 300 PFU units of VSVΔG/LASVGP were added to Vero E6
cells in a 12-well tissue culture plate and incubated for 1 h at 4 °C. The
serially diluted rabbit immune antisera were then added to the attached
viruses. After incubation at 4 °C for 1 h, and additional incubation at 37 °C
for 0.5 h, the inoculum was removed and, after washing the cells with PBS,
fresh DMEM supplemented with 2% FBS was added. Cells were then
incubated at 37 °C with 5% CO2, and the cell lysates were harvested 24 h
post infection. For the detection of viral proteins, the samples were
analyzed by SDS-PAGE and western blot analysis. The Odyssey Infrared
Imaging System (LI-COR Biosciences) was used for visualization of detected
proteins.
Reporting summary
Further information on experimental design is available in the Nature
Research Reporting Summary linked to this article.
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